You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Emerging Horizons in Cancer Immunotherapy

Immunotherapy has been shown to be beneficial in the first- and second-line setting for multiple solid tumor types. The quickly changing landscape of available therapies and indications can make selection and use of immunotherapies challenging. Additionally, the understanding of combination treatments and management of immune-related adverse reactions is quickly evolving.

Supported by an independent educational grant from

AstraZeneca Pharmaceuticals LP

CME Activities

Polling Question

Related Resources

Steering Committee

Jared Weiss, MD

Steering Committee Chair

Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, United States

Fabrice Barlesi, MD, PhD

Professor of Medicine, Aix-Marseille University, Marseille, France

Joshua Bauml, MD

Assistant Professor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Matthew D. Galsky, MD

Professor of Medicine; Director of Genitourinary Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, United States

Amanda Psyrri, MD, PhD, FACP

Associate Professor of Medicine; Chief of Medical Oncology, National Kapodistrian University of Athens Medical School, Attikon University Hospital, 2nd Dept. of Internal Medicine, Propaedeutic Research Institute, Athens, Greece

Neil H. Segal, MD, PhD

Deputy Director, Immunotherapeutics Group; Assistant Attending, Gastrointestinal Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States